We used multiple doses of MIP for immunotherapy as pre-existent Th2-driving physiological condition like infection with M. tuberculosis might overshadow the efficacy of a single dose of immunomodulator that could otherwise be effective in eliciting strong anti-TB Th1 response. This evidence concerns the gene MIP and tuberculosis.